Application of PLA2G4F protein as therapeutic target in preparation of medicine for treating triple negative breast cancer
By inhibiting the PLA2G4F protein and using siRNA to target the treatment of triple-negative breast cancer, the targeted treatment problems in the existing technology were solved, and the proliferation and lipid metabolism of triple-negative breast cancer cells were significantly inhibited, providing new therapeutic targets and drugs. R&D direction.
Patent Information
- Application Number
- CN202411321116.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-23
- Publication Date
- 2024-11-26
AI Technical Summary
The treatment of triple-negative breast cancer has high recurrence rates and chemotherapy resistance. It is difficult for the prior art to effectively target its specific therapeutic targets, resulting in poor treatment results.
The PLA2G4F protein is used as a therapeutic target to selectively inhibit the expression of PLA2G4F through siRNA, thereby inhibiting the vitality, proliferation and migration of triple-negative breast cancer cells, affecting lipid metabolism, and preparing drugs for triple-negative breast cancer treatment.
It significantly reduces cell proliferation, increases apoptosis, damages TNBC cancer cells, inhibits lipid formation and metabolic gene expression, provides new drug treatment targets, and is of great significance to subsequent drug research and development and clinical treatment.
Smart Images

Figure BDA0005053930580000041 
Figure BDA0005053930580000051 
Figure HDA0005053930590000011
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to the application of PLA2G4F protein as a therapeutic target in the preparation of a drug for treating triple-negative breast cancer. Background Art
[0002] Triple-negative breast cancer (TNBC) is defined by the loss of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. Its clinical course is different, with high invasiveness, early recurrence, and poor prognosis, which poses a major challenge in the treatment of clinical oncology. Although some TNBC patients benefit from surgical treatment, they still have a high recurrence rate and chemotherapy resistance in subsequent treatment. Heterogeneous TNBC can be developed into new therapeutic targets. A promising avenue is the exploration of metabolic gene signatures. In fact, previous reports of single-cell transcriptome analysis have shown metabolic heterogeneity in breast cancer, and targeting several metabolic genes can inhibit tumor progression and modulate the tumor microenvironment. Therefore, there is an urgent need to characterize comprehensive cell-specific metabolic reprogramming of TNBC.
[0003] Metabolic reprogramming is an emerging hallmark of cancer that plays a key role in various aspects of tumor progression, including triple-negative breast cancer (TNBC). Accumulating evidence suggests that tumor metabolic reprogramming occurs in both malignant and non-malignant cells in the tumor microenvironment, forming an integrated metabolic regulatory network with distinct cellular metabolic characteristics. Altered metabolite profiles not only regulate energy dynamics but also coordinate signal transduction in the tumor microenvironment, thereby forming a vicious cycle in tumor progression. Beyond the local tumor site, the complex reprogramming of tumor metabolism can have a profound impact on the systemic metabolic landscape of the host, potentially leading to cachexia and impaired anti-tumor immunity. Targeting metabolism is increasingly recognized as a promising cancer therapeutic approach.
[0004] Lipid metabolism plays a crucial role in the progression of TNBC. Increased fatty acid synthesis helps generate structural lipids necessary for cell membrane formation, leading to lipid accumulation during cell proliferation. In addition, alterations in cancer cell lipid metabolism may also lead to immune evasion.
[0005] PLA2G4F is a promising target due to its specific expression in malignant cells and its strong association with the carcinogenic process. PLA2G4F has been reported to have calcium-dependent phospholipase and lysophospholipase activities and has a potential role in membrane lipid remodeling and the biosynthesis of lipid mediators.
[0006] Purpose of the Invention
[0007] In view of the shortcomings and deficiencies in the prior art, the object of the present invention is to provide an application of PLA2G4F protein as a therapeutic target in the preparation of a drug for treating triple-negative breast cancer.
[0008] The technical solution of the present invention is as follows:
[0009] Application of PLA2G4F protein as a therapeutic target in the preparation of drugs for the treatment of triple-negative breast cancer.
[0010] The NCBI-gene number of PLA2G4F in the present invention is 255189, and the gene sequence of PLA2G4F can be searched in NCBI by using this number.
[0011] Furthermore, the therapeutic target: siRNA selectively inhibits PLA2G4F at the transcriptional and translational levels.
[0012] Furthermore, the siRNA includes siRNA1, siRNA2, and siRNA3.
[0013] The sequence of siRNA1 includes that shown in SEQ ID NO: 1;
[0014] The sequence of siRNA2 includes that shown in SEQ ID NO: 2;
[0015] The sequence of siRNA3 is shown in SEQ ID NO:3.
[0016] Furthermore, the siRNA is siRNA2.
[0017] Furthermore, the drug inhibits the expression of PLA2G4F, thereby inhibiting the viability, proliferation and migration of triple-negative breast cancer cells.
[0018] Furthermore, the inhibition of PLA2G4F resulted in a significant reduction in lipid formation and also suppressed the expression of lipid metabolism genes in triple-negative breast cancer cells.
[0019] A kit for treating triple-negative breast cancer, comprising any of the siRNAs described above.
[0020] Compared with the prior art, the present invention has the following beneficial effects:
[0021] The present invention discloses that three siRNAs selectively inhibit PLA2G4F at the transcription and translation levels, and that inhibition of PLA2G4F can significantly reduce cell proliferation, increase apoptosis, and also damage TNBC cancer cells. Specifically, inhibition of PLA2G4F leads to a significant reduction in lipid formation and also inhibits the expression of lipid metabolism genes in TNBC cells.
[0022] The present invention provides a new drug treatment target for the treatment of triple-negative breast cancer, and has important scientific significance for subsequent drug development, clinical treatment, etc. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 Schematic diagram of 42,512 cells from 10 TNBC patients in Example 1 being divided into 9 cell types according to typical lineage markers;
[0024] Figure 2 The UMAP graph shows the log-normalized expression levels of marker genes for normal epithelial cells (EPCAM, ANKRD30A), cancer epithelial cells (EPCAM), T cells (CD3D), myeloid cells (CD68), B cells (MS4A1), plasmablasts (JCHAIN), endothelial cells (PECAM1), cancer-associated fibroblasts (PDGFRA, COL1A1), and perivascular cell-like cells (MCAM, ACTA2, PDGFRB);
[0025] Figure 3 Schematic diagram of cell type-specific expression of each key metabolic gene;
[0026] Figure 4 Schematic diagram of PLA2G4F expression in single-cell sequencing datasets (DOR=23.7);
[0027] Figure 5 Schematic diagram showing that three candidate small interfering RNAs (siRNAs) inhibited PLA2G4F expression (RNA level) in both MDA-MB-231 and MDA-MB-468 cell lines;
[0028] Figure 6 Schematic diagram showing that three candidate small interfering RNAs (siRNAs) inhibited the expression (protein level) of PLA2G4F in both MDA-MB-231 and MDA-MB-468 cell lines;
[0029] Figure 7 Schematic diagram of cell viability in two cell lines, MDA-MB-231 and MDA-MB-468;
[0030] Figure 8 Schematic diagram of apoptosis detection in two cell lines, MDA-MB-231 and MDA-MB-468;
[0031] Fig. 9 Schematic diagram of transwell assay to detect the migration ability of MDA-MB-231 and MDA-MB-468 cell lines, and image J to detect the number of migrated cells;
[0032] Fig.10 Schematic diagram of oil red staining to detect lipid accumulation in MDA-MB-231 and MDA-MB-468 cell lines;
[0033] Fig.11 Schematic diagram of relative expression of RNA level of genes related to lipid metabolism;
[0034] Fig.12 This is a schematic diagram of solid tumors in each group of nude mouse tumor formation experiment in Example 2;
[0035] Fig.13 This is a schematic diagram of the tumor volume of nude mice tumor formation experiment during the experiment of Example 2;
[0036] Fig.14 This is a schematic diagram of the in vitro tumor weight in the nude mouse tumor formation experiment in Example 2. DETAILED DESCRIPTION
[0037] The present invention is further described below in conjunction with the accompanying drawings and embodiments.
[0038] Embodiment 1:
[0039] 1. Experimental methods (the experimental methods used in this example, such as bioinformatics analysis, cell culture and lentiviral transfection, quantitative PCR, cell migration, etc., are conventional methods and techniques in the art):
[0040] A. Bioinformatics Analysis:
[0041] The spatial distribution of specific genes was evaluated using the diagnostic odds ratio (DOR). For each gene, the DOR was calculated by binarizing the expression values, where normalized expression values greater than 0 were positive and 0 was negative. To prevent undefined values, a pseudo count of 0.5 was added, and the DOR was calculated as follows:
[0042]
[0043] Among them, true positive (TP) represents the number of cells in the group that express the 298 genes, false positive (FP) represents the number of cells outside the group that express the gene, false negative (FN) represents the number of cells in the group that do not express the gene, and true negative (TN) represents the number of cells outside the group that do not express the gene.
[0044] B. Cell Culture and Lentiviral Transfection
[0045] MDA-MB-231 and MDA-MB-468 triple-negative breast cancer cell lines were obtained from ATCC and cultured in high-glucose medium (DMEM) supplemented with 10% fetal calf serum (FCS), 1% sodium pyruvate, and 1% 306 penicillin / streptomycin (Thermo, USA). All cultures were cultured in a humidified incubator at 37°C and 5% CO2.
[0046] Small interfering RNA (siRNA) targeting PLA2G4F and negative control were provided by Shanghai Genetron. The sequences of the three siRNAs (5′-3′, sense strand sequence, where the antisense strand is the complementary sequence and is not listed here) are:
[0047] si-1 (siRNA1): GGCUACAGUACUACACUCAT (SEQ ID NO: 1);
[0048] si-2 (siRNA2):CCCUAUGGCAUGAUGAACUTT (SEQ ID NO: 2);
[0049] si-3 (siRNA3): GGGAAACCUACCCAUACUATT (SEQ ID NO: 3).
[0050] Quantitative PCR and western blot (WB) were used to verify the expression of PLA2G4F at the mRNA and protein levels.
[0051] C. Quantitative PCR (QPCR)
[0052] Total RNA from tissues and cells was extracted using RNA Isolator Total RNA Extraction Reagent from Novozymes, and reverse transcription was performed using PrimeScript RT Master Mix (TaKaRa, Japan) according to the instructions.
[0053] QPCR was detected using SYBR Green Mix (Life Technology, 318 USA) and quantified using ABI 7500 Real-Time PCR System (Applied Biosystems, USA).
[0054] The relative expression of each gene was normalized to Actin using the 2-ΔΔCt method (GAPDH in Table 1 was used as an internal reference).
[0055] The specific primer sequences are shown in Table 1 (all purchased from Shanghai Biotechnology).
[0056]
[0057] D. Cell migration assay
[0058] The transfected cells were inoculated in 200 μL of culture medium without fetal bovine serum, and the wells on the 24-well plate were inoculated in 500 μL of complete culture medium containing 10% fetal bovine serum. After 48 hours of migration, the cells in each well were fixed and stained with hematoxylin. The cells were washed and the cells outside the membrane were observed under a microscope. Three independent experiments were performed.
[0059] E. Cell Viability Assay
[0060] The cells transfected in different ways were seeded in 96-well plates at a rate of 5000 cells / well and incubated at 37°C. The cell viability was measured every 12 hours using a CCK8 kit (Abbkine). The absorbance was measured at 450 nm using a microplate reader.
[0061] F. Oil red staining
[0062] Cell lines were seeded in 96-well plates as described above. 24 hours after siRNA transfection, the lipid droplets in the cells in the wells were stained using the Oil Red O staining kit. The steps were as follows: Wash the cells 3 times with PBS and fix the cells for 30 minutes. Discard the liquid and soak the cells in 60% isopropanol for 30 seconds. Add Oil Red staining solution to each well for 30 minutes and incubate with hematoxylin. Finally, rinse in running water for 1 minute and take pictures under a microscope.
[0063] G. Cell apoptosis assay
[0064] Flow cytometry was used to detect the level of cell apoptosis. Tumor cells were transfected with siRNA and incubated for 48 hours. Cells were collected, stained using the Annexin V / FITC kit (Abbkine), and analyzed by flow cytometry.
[0065] 2. Experimental results:
[0066] 1. Given that malignant cells are primarily responsible for reprogramming the metabolism of the tumor microenvironment, identifying candidate targets specifically expressed in these cells is crucial for effective therapeutic intervention.
[0067] To identify the cellular origin and expression specificity of key metabolic features in TNBC, we analyzed an independent breast cancer scRNA-seq dataset. After quality control, normalization, clustering, and annotation, 42,512 cells from 10 TNBC patients were divided into 9 cell types based on typical lineage markers ( Figure 1 and Figure 2 Using the differential expression ratio (DOR) approach, we assessed the cell type specificity of key metabolic genes, which showed significant cell type specificity.
[0068] Among them, FOLH1 (DOR = 15.3) and AK5 (DOR = 24.8) were mainly expressed in normal epithelial cells, while GLDC (DOR = 3.3), PLA2G4F (DOR = 23.7), PLCH1 (DOR = 15.3), CYP24A1 (DOR = 33.1) and psat1 (DOR = 10.9) were mainly expressed in cancer epithelial cells ( Figure 3 and Figure 4 ).
[0069] In addition, myeloid cells were the main source of LTC4S (DOR = 7.34), while cancer-associated fibroblasts (CAFs) were the main source of COX7A1 (DOR = 14.5) and ENPP6 (DOR = 43.2). Figure 3 ).
[0070] 2. Considering the specific expression of PLA2G4F in TNBC epithelial cells and its correlation with poor prognosis, we studied the tumorigenic effect of PLA2G4F in vitro.
[0071] In the TNBC cell lines MDA-MB-231 and MDA-MB-468, three candidate small interfering RNAs (siRNAs) selectively inhibited PLA2G4F at the transcriptional and translational levels (e.g. Figures 5 to 11 ). Among them, siRNA2 was the most effective in reducing PLA2G4F expression in both cell lines and was selected for further study (e.g. Figure 5 and Figure 6 shown).
[0072] In two TNBC cell lines (MDA-MB-231 and MDA-MB-468), inhibition of PLA2G4F significantly reduced cell proliferation and increased apoptosis (p < 0.001) (Fig. Figure 7 and Figure 8 ).
[0073] Furthermore, inhibition of PLA2G4 significantly impaired cancer cell migration (p < 0.001, e.g. Fig. 9 shown).
[0074] 3. Considering the specific expression of PLA2G4F in TNBC epithelial cells and its correlation with poor prognosis, we studied the role of PLA2G4F in lipid metabolism in vitro. We next explored the effect of PLA2G4F on lipid metabolic reprogramming of TNBC cells.
[0075] Note: The above (such as Figure 5 and Figure 6 ) was mentioned as siRNA 2 was the most effective in reducing PLA2G4F expression in both cell lines and was selected for further study.
[0076] pass Fig.10 It can be seen that inhibition of PLA2G4F leads to a significant decrease in lipid formation.
[0077] We evaluated the effects of PLA2G4F inhibition on key lipid metabolism genes, including fatty acid synthesis (ACACA, ACACB), fatty acid oxidation (CPT1A, CPT2), cholesterol synthesis (HMGCR), triglyceride synthesis (DGAT1, DGAT2), and lipolysis (LIPE). Inhibition of PLA2G4F broadly suppressed the expression of eight lipid metabolism genes (e.g. Fig.11 ), emphasizing the key role of PLA2G4F in regulating lipid metabolism in TNBC cells.
[0078] Example 2: Animal Experiment
[0079] BALB / c nude mice were purchased from the Model Animal Research Institute, Nanjing University Medical School.
[0080] A BALB / c nude mouse xenograft tumor model was established using MDA-MB-231.
[0081] The experimental group used shPLA2G4F to knock out the PLA2G4F gene, so that PLA2G4F was lowly expressed in the cells) stably transfected cell line, and the control group used an empty cell line.
[0082] Schematic diagram of tumors in the experimental and control groups Fig.12 As shown; the tumor volume of nude mice was continuously monitored during the experiment ( Fig.13 and Fig.14 , **P<0.01) and the tumor weight was recorded. In the nude mouse transplant tumor model, compared with the control group, the volume and weight of the tumor in the nude mouse of the shPLA2G4F stable cell line were statistically significant, indicating that the inhibition of PLA2G4F expression can significantly inhibit the growth of nude mouse tumors.
[0083] Conclusion: In summary, the present invention first analyzed the origin of key metabolic cell subpopulations through single-cell sequencing data sets, and verified at the cellular and animal levels that inhibiting PLA2G4F can inhibit TNBC proliferation and reprogram lipid metabolism.
[0084] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. Application of PLA2G4F protein as a therapeutic target in the preparation of drugs for the treatment of triple-negative breast cancer.
2. The use according to claim 1, characterized in that The therapeutic target: siRNA selectively inhibits PLA2G4F at the transcriptional and translational levels.
3. The use according to claim 2, characterized in that The siRNA includes siRNA1, siRNA2, and siRNA3. The sequence of siRNA1 includes that shown in SEQ ID NO: 1; The sequence of siRNA2 includes that shown in SEQ ID NO: 2; The sequence of siRNA3 is shown in SEQ ID NO:
3.
4. The use according to claim 3, characterized in that The siRNA is siRNA2.
5. The use according to any one of claims 1 to 4, characterized in that: The drug inhibits the expression of PLA2G4F, thereby inhibiting the viability, proliferation and migration of triple-negative breast cancer cells.
6. The use according to claim 5, characterized in that The inhibition of PLA2G4F resulted in a significant reduction in lipid formation and also suppressed the expression of lipid metabolism genes in triple-negative breast cancer cells.
7. A kit for treating triple-negative breast cancer, characterized in that: The method comprises the siRNA as described in any one of claims 2 to 4.
